AI-driven drug research and development (R&D) is breaking new ground, providing faster and more effective treatment options for more patients worldwide
SHENZHEN & HONG KONG, China, Nov. 24, 2022 /PRNewswire/ — XtalPi announced today that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumor vaccine R&D platform to Improve the discovery and design capabilities of tumor vaccines and accelerate the development of more vaccine types. The goal of this collaboration is to realize precision treatment for patients worldwide.
According to public information, there were nearly 20 million newly diagnosed cancer patients worldwide in 2021, of which about 4.5 million cases came from ChinaMany cancer types lead to detrimental outcomes, with high morbidity and mortality, and there remains a large unmet clinical need. Tumor vaccines targeting different tumor neoantigens, tumor-associated antigens (TAA) and tumor-specific antigens (TSA) in patients can be Designed for use as immunotherapy, to activate the patient’s own specific immune responses.
Currently, there are only two therapeutic tumor vaccines— sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for bladder cancer, as well as preventive tumor vaccines against human papillomavirus infection and hepatitis B infection approved by the US Administ and Drug FDA). Recently, several other tumor vaccines have entered clinical development and evidence of efficacy has begun to emerge.
According to Mordor…
